ESG Data｜Sustainability｜Hisamitsu Pharmaceutical co.,inc.

Environment

Hisamitsu Pharmaceutical Group’s CO₂ emissions（Scope 1 & 2）

	Unit	FY2022	FY2023	FY2024
Hisamitsu Pharmaceutical Group*¹	t	34,452	34,439	34,017
Group emission intensity (CO₂ emissions/Consolidated net sales)	t/million yen	0.27	0.24	0.22
Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated]	t	22,140	22,468	21,814
Emission intensity of Hisamitsu Pharmaceutical, nonconsolidated (CO₂ emissions/nonconsolidated net)	t/million yen	0.24	0.23	0.21
Kyushu Head Office	t	11,736	12,756	10,470
Utsunomiya Factory	t	6,242	6,132	6,151
SAGA Global Research Center*	t	2,132	1,790	3,717
Tokyo Head Office / Branches and Sales Offices	t	2,030	1,790	1,476
Japan subsidiaries*²	t	1,576	1,962	1,815
Overseas subsidiaries*³	t	10,736	10,009	10,388

*: Tsukuba Laboratories for FY2022-FY2023

*1 The data above excludes domestic and overseas subsidiaries and overseas sales offices that have a negligible impact on the calculation of CO₂ emissions.
*2 Three companies: CRCC Media Co., Ltd., Saga City-Vision Co., Ltd., and SAGA Hisamitsu Springs Co., Ltd.
*3 Four companies with manufacturing plants: Noven, Hisamitsu Indonesia, Hisamitsu Vietnam, and Hisamitsu Brazil

CO₂ emissions in the supply chain
(Hisamitsu Pharmaceutical Co., Inc.
[Non-consolidated]; Scope 1, 2, and 3)

	Unit	FY2022	FY2023	FY2024
Scope 1（Direct emissions）	t	7,862	7,186	4,393
Scope 2（Indirect emissions）	t	14,278	15,282	17,421
Scope 3	t	98,488	111,566	97,732
Category 1: Purchased goods and services	t	49,823	46,290	41,246
Category 2: Capital goods	t	11,651	31,891	36,669
Category 3: Fuel- and energy-related activities not included in Scope 1 or 2	t	4,885	4,763	4,775
Category 4: Transportation, delivery (upstream)	t	2,234	2,197	1,340
Category 5: Waste from business	t	2,433	2,196	2,061
Category 6: Business travel	t	340	610	690.6
Category 7: Employee commuting	t	271	286	296.5
Category 8: Leased assets (upstream)	t	ー	ー	ー
Category 9: Transportation and delivery (downstream)	t	33	35	22
Category 10: Processing of sold products	t	ー	ー	ー
Category 11: Use of sold products	t	ー	ー	ー
Category 12: End-of-life treatment of sold products	t	26,818	23,298	10,632^*2
Category 13: Leased assets (downstream)	t	ー	ー	ー
Category 14: Franchises	t	ー	ー	ー
Category 15: Investments	t	ー	ー	ー
Total	t	120,628	134,034	119,546

*1 The values listed in the Database of emission intensity for Calculating Each Organization’s Greenhouse Gas Emissions throughout Its Supply Chain (Ver 3.2), Ministry of the Environment
*2 Until FY2023, all calculations were based on incineration disposal, but from FY2024, we will use the emission intensity provided by the Ministry of the Environment, which is based on the actual state of waste disposal (incineration, landfill, recycling).

Energy consumption
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

	Unit	FY2022	FY2023	FY2024
Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated]	kL	11,844	10,976	11,445
(Non-consolidated) Energy consumption per unit (energy consumption / non-consolidated sales [million yen])	kL/million yen	0.13	0.11	0.11
Kyushu Head Office (Crude oil equivalent)	kL	6,687	5,932	5,439
Electricity	Mwh	20,871	20,367	19,148
Gas (LNG)	㎥	291,363	690,506	747,613
Heavy oil	kL	1,093	562	336
Utsunomiya Factory (Crude oil equivalent)	kL	3,168	3,099	3,133
Electricity	Mwh	10,679	10,366	10,593
Steam	t	15,627	16,209	17,098
SAGA Global Research Center* (Crude oil equivalent)	kL	1,051	959	1,902
Electricity	Mwh	3,188	3,198	7,528
Gas（LPG）	㎥	ー	ー	78,927
Kerosene	kL	272	262	21
Tokyo HO/Branches and Sales offices	kL	938	986	971
Electricity	Mwh	480	414	429
Gas (LNG)	㎥	1,298	1,301	1,400
Gasoline	kL	674	640	583

*: Tsukuba Laboratories for FY2022-FY2023

Energy consumption by type
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

Energy type	Unit	FY2022	FY2023	FY2024
Purchased electricity	MWh	35,656	35,345	37,896
Steam supplied from an external heat source	GJ	38,188	42,555	43,089
City gas	㎥	363,094	698,625	749,013
LPG	kg	5,835	6,657	149,670
Heavy oil A	kL	1,044	589	336
Gasoline	kL	657	640	586
Light oil	kL	1	1	1
Kerosene	kL	272	262	21

Energy consumption at overseas factories

Overseas subsidiaries	Energy	Unit	FY2022	FY2023	FY2024
Noven	Electricity	MWh	10,302	10,387	9,386
	Gas （LNG）	㎥	323,955	406,870	340,940
	Light oil	kL	0.0	0.0	0.0
Hisamitsu Vietnam	Electricity	MWh	3,773	3,573	2,923
	Gas （LPG）	㎥	48,797	30,648	32,801
	Light oil	kL	2.7	1.7	3.6
Hisamitsu Indonesia	Electricity	MWh	3,274	3,439	3,756
	Gas （LPG）	㎥	ー	ー	222,384
	Light oil	kL	256	312	86
Hisamitsu Brazil	Electricity	MWh	2,489	3,501	3,696
	Gas （LPG）	㎥	4,156	6,822	522
	Light oil	kL	36	58	75

Water withdrawal by water source and drainage volume by destination (Hisamitsu Pharmaceutical Group)

		Unit	FY2022	FY2023	FY2024
Water withdrawal by water source	Total water withdrawal	㎥	272,886	280,951	283,007
	Municipal potable water	㎥	186,549	187,843	184,400
	Industrial water	㎥	49,332	55,920	60,734
	Surface water from rivers, lakes, natural ponds, etc.	㎥	0	0	0
	Groundwater from wells and boreholes	㎥	37,005	37,188	37,873
	Used quarry water collected in the quarry	㎥	0	0	0
	External wastewater	㎥	0	0	0
	Harvested rainwater	㎥	0	0	0
	Sea water, water extracted from the sea or the ocean	㎥	0	0	0
Drainage volume by destination	Total Drainage volume*¹	㎥	86,520	131,351	147,542
	Sewage	㎥	86,520	88,625	119,564
	Rivers*²	㎥	0	42,726	27,978
	Ocean	㎥	0	0	0
	Surface water	㎥	0	0	0
Amount recycled		㎥	39,079	39,495	32,689

*1 Total of the drainage volumes monitored.
*2 Hisamitsu Pharmaceutical Co., Inc. (non-consolidated) discharges water that meets the discharge standards into rivers, but does not monitor the volume.

Water withdrawal and drainage volumes at overseas factories

		Unit	FY2022	FY2023	FY2024
Total of overseas subsidiaries	Water withdrawal	㎥	98,877	107,850	97,382
Total of overseas subsidiaries	Drainage volume	㎥	ー	44,344	49,886
Noven	Water withdrawal	㎥	22,240	20,365	31,081
Noven	Drainage volume	㎥	ー	ー	ー
Hisamitsu Vietnam	Water withdrawal	㎥	50,519	54,627	33,871
Hisamitsu Vietnam	Drainage volume	㎥	ー	38,239	23,710
Hisamitsu Indonesia	Water withdrawal	㎥	17,051	32,378	31,950
Hisamitsu Indonesia	Drainage volume	㎥	ー	5,913	26,176
Hisamitsu Brazil	Water withdrawal	㎥	9,067	480	480
Hisamitsu Brazil	Drainage volume	㎥	ー	192	ー

*Sampled water: Tap water for Noven, Hisamitsu Vietnam and Hisamitsu Indonesia; well water for Hisamitsu Brazil

Water withdrawals in water-stressed areas

Water stress level	Base	Unit	FY2022	FY2023	FY2024
Low（＜10%）	Hisamitsu Brazil	㎥	9,067	480	480
Low - medium（10 - 20%）	Tosu Factory, SAGA Global Research Center, Noven, Hisamitsu Vietnam, Hisamitsu Indonesia	㎥	196,221	207,356	214,466
Medium - high（20 - 40%）	Utsunomiya Factory	㎥	58,256	64,040	68,061
High（40 - 80%）	N/A	㎥	ー	ー	ー
Extremely high（＞80％）	N/A	㎥	ー	ー	ー

Water intake, drainage volume, and water pollutant emissions
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

	Unit	FY2022	FY2023	FY2024
Water withdrawal	㎥	174,009	173,101	185,625
Water consumption intensity (Water consumption/nonconsolidated net sales)	㎥/million yen	1.87	1.79	1.81
Drainage volume	㎥	86,520	87,007	97,656
BOD*¹ emissions	t	8.6	10.3	9.1
SS*² emissions	t	2.2	1.4	0.9

*1 BOD (biological oxygen demand): Value representing the amount of oxygen consumed when organics are decomposed by microorganisms in water
*2 SS (suspended solids): Volume of solid particles whose diameter is 2 mm or under that remain in suspension in water

Total waste emissions / Final waste disposal volume / Recycling rate
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

	Unit	FY2022	FY2023	FY2024
Total waste generated	t	3,722	3,358	3,329
Amount of resources recycled (Amount of valuable resources)	t	541.0	476.6	484.3
Recycling rate (Valuable resource rate)	%	14.5	14.2	14.5
Final waste disposal volume	t	8.0	7.4	6.3
Final waste disposal rate	%	0.21	0.22	0.19
Generation intensity (Total amount of waste generated/Non-consolidated net sales)	t/million yen	0.04	0.03	0.03

Waste emissions at overseas factories

Overseas subsidiaries		Unit	FY2022	FY2023	FY2024
Total of overseas subsidiaries	Total waste generated	t	1,844	1,243	1,532
Noven	Total waste generated	t	399	156	413
	Amount of industrial waste	t	347	86	354
	Amount recycled	t	52	70	59
Hisamitsu Vietnam	Total waste generated	t	363	280	249
	Amount of industrial waste	t	323	245	213
	Amount recycled	t	40	35	36
Hisamitsu Indonesia	Total waste generated	t	444	448	443
	Amount of industrial waste	t	399	391	375
	Amount recycled	t	45	57	68
Hisamitsu Brazil	Total waste generated	t	638	359	427
	Amount of industrial waste	t	593	321	397
	Amount recycled	t	45	38	30

Management of Specified Chemical Substances
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

		Unit	FY2022	FY2023	FY2024
Toluene (PRTR^＊ Substances)	Handling volume	t	3.7	3.4	1.3
	Emission into the air	t	0.2	0.2	0.1
	Waste disposal	t	3.5	3.2	0.2

*PRTR system: A system established under the “Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof” that requires the release amounts of certain chemical substances into the environment to be monitored and reported to the government

Air pollutant emissions
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

	Unit	FY2022	FY2023	FY2024
SOx (sulfur oxide) emissions	t	0.7	0.5	0.003
NOx (nitrogen oxide) emissions	t	1.8	1.7	0.4
Emissions of ozone-depleting substances(ODS)	t	0	0	0

Acquisition status of ISO 14001 certification

Certification scope (organization name)	Certification acquisition date	Acquisition rate
Kyushu Head Office	December 24, 1999	Acquisition rate at three domestic pharmaceutical manufacturing plants and research facilities: 100%.
Utsunomiya Factory	December 22, 2000
SAGA Global Research Center	November 14, 2025

Acquisition status of ISO 45001 certification

Certification scope (organization name)	Certification acquisition date	Acquisition rate
Kyushu Head Office	December 25, 2019	Acquisition rate at three domestic pharmaceutical manufacturing plants and research facilities: 100%.
Utsunomiya Factory	December 25, 2019
SAGA Global Research Center	November 20, 2025

Compliance with environmental laws and regulations (Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

	Unit	FY2022	FY2023	FY2024
Number of violations of environmental laws and regulations	Case	0	0	0
Number of violations related to water quality and quantity	Case	0	0	0

Environmental accounting
Environmental Conservation Cost
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])Unit: 1,000 yen

Category	FY2022			FY2023			FY2024
Category	Facilities	Expenses	Total	Facilities	Expenses	Total	Facilities	Expenses	Total
Pollution prevention	0	33,164	33,164	0	46,402	46,402	0	23,236	23,236
Global environmental protection	307,300	98,274	405,574	274,390	174,596	448,986	432,948	143,022	575,970
Resource recycling	273,708	155,529	429,237	172,858	166,701	339,559	172,357	151,284	323,641
Upstream/Downstream	0	16,359	16,359	0	20,119	20,119	0	18,669	18,669
Management activities	0	68,214	68,214	0	68,150	68,150	0	63,198	63,198
Social activities	0	5,914	5,914	0	4,897	4,897	0	919	919
Environmental damage response	0	488	488	0	482	482	0	235	235
Other	0	0	0	0	0	0	0	0	0
Total	581,008	377,942	958,950	447,248	481,347	928,595	605,305	400,563	1,005,868

Environmental Conservation Effect
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

	Unit	FY2022	FY2023	FY2024
Energy consumption (crude oil equivalent)	kL	11,170	11,517	11,445
CO₂ emissions	t	22,140	22,468	21,814
SOx emissions	t	0.7	0.5	0.003
NOx emissions	t	1.8	1.7	0.4
Water withdrawal	1,000㎥	174	173	186
Drainage volume	1,000㎥	87	87	98
BOD emissions	t	8.6	10.3	9.1
Waste emissions	t	3,722	3,358	3,329

Percentage of hybrid vehicles in all corporate sales vehicles
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

	Unit	FY2022	FY2023	FY2024
Percentage of hybrid vehicles	%	93.5	98.8	99.8

Society

Employee data (Consolidated)

	Unit	FY2022	FY2023	FY2024
Consolidated number of employees	Person	2,769	2,759	2,799
Number of domestic employees	Person	1,579	1,568	1,553
Number of overseas employees	Person	1,190	1,191	1,246
Number of male employees*	Person	1,654	1,640	1,649
Number of female employees*	Person	1,115	1,119	1,150
Ratio of female employees*	%	40.3	40.6	41.1

* Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated]/Domestic subsidiaries: As of the end of February; Overseas subsidiaries: As of the end of December

Employee data
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated]; As of the end of February each fiscal year)

	Unit	FY2022	FY2023	FY2024
Number of employees	Person	1,521	1,506	1,488
Number of male employees	Person	1,070	1,042	1,012
Number of female employees	Person	451	464	476
Ratio of female employees	%	29.7	30.8	32.0
Ratio of female managers*	%	7.9	7.8	9.4
Average age	Age	38.9	39.4	39.2
Average length of service	Year	15.3	15.8	15.7
Average years of service for men	Year	15.7	16.3	16.5
Average years of service for women	Year	14.5	14.6	13.9
Elderly employment rate	%	3.29	4.56	5.26
Employment rate of persons with disabilities	%	1.95	2.31	2.55
Number of new employees	Person	10	54	68
Number of new male employees	Person	4	26	31
Number of new female employees	Person	6	28	37
Ratio of new female employees	%	60.0	51.9	54.4
Mid-career hiring rate	%	55	16	14
Voluntary turnover rate	%	3.7	4.0	3.6

* As of the end of March each fiscal year

Gender wage difference
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated]; Ratio of women's wages to men's wages)

	Unit	FY2022	FY2023	FY2024
Regular employees	%	76.1	74.3	73.8
Part-time/fixed-term employees	%	92.6	90.0	89.5
All employees	%	75.7	74.5	74.1

Training
(Hisamitsu Pharmaceutical Co., Inc.
[Non-consolidated]）

	Unit	FY2022	FY2023	FY2024
Total training time*	hours	4,841.5	10,671.0	12,038.0
Training time per employee*	hours/person	3.2	7.1	8.1

* Training sessions organized by the Human Resources Division

Data related to work-life management
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

	Unit	FY2022	FY2023	FY2024
Number of days of paid leave taken	Day	13.3	13.4	13.0
Rate of paid leave taken	%	72.1	71.7	69.3
Number of employees taking maternity leave	Person	31	24	24
Number of employees taking childcare leave	Person	66	48	47
Male	Person	29	24	25
Female	Person	37	24	22
Rate of employees taking childcare leave	%	72	61	67
Rate of male employees taking childcare leave	%	50	42	54
Rate of female employees taking childcare leave	%	108	109	91
Rate of return to work after childcare leave	%	98.4	100.0	98.2

Data related to occupational safety and health
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

	Unit	FY2022	FY2023	FY2024
Number of workplace accidents	Case	8	8	8
Number of workplace accidents requiring absence from work	Case	3	0	0
Workplace accident frequency rate*	%	0.85	0.00	0.00

*Number of casualties due to workplace accidents / Total work hours x 1,000,000

Data related to group support activities
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

Support activities for NPOs and civic organizations by Hisamitsu-Hot-Heart Club

	Unit	FY2022	FY2023	FY2024
Number of groups supported	Group	39	41	39
Donation amount	1,000 yen	3,900	4,100	3,900

Data related to disaster relief activities and fundraising activities
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

	Unit	FY2022	FY2023	FY2024
Donation*¹	Yen	16,595,993	1,435,394	ー
Provision of supplies*²	Pieces / Bottles	ー	(1)28,800sheets (2)250boxes (3)70pieces	ー
International charity drive*³	Yen	601,975	601,975	533,825

*1: Including donations from Hisamitsu-Hot-Heart Club and from employees
*2: Provision of supplies based on the Agreement of Support and Cooperation at the Time of a Disaster signed by the Japanese Red Cross Society in January 2020
(1)Hisamitsu_Ⓡ Refresh Body Sheet, (2)Heating device Jikabari_Ⓡ, (3)Feitas_Ⓡ ACTIVE SUPPORTER

Governance

Directors / Corporate Auditors
(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated]; As of the end of February each fiscal year)

	Unit	FY2022	FY2023	FY2024
Directors	Person	9	9	9
Outside Directors	Person	3	3	3
Female Directors	Person	0	1	1
Ratio of Outside Directors	%	33.3	33.3	33.3
Corporate Auditors	Person	4	4	4
Outside Corporate Auditors	Person	2	2	2
Ratio of Outside Corporate Auditors	%	50.0	50.0	50.0
Executive officers	Person	13	16	22
Female executive officers	Person	0	0	1
Percentage of female executive officers	%	0.0	0.0	4.5
Number of meetings of the Board of Directors	Time	7	7	7
Board of Directors meeting attendance rate (all Directors)	%	97.0	100.0	96.8
Board of Directors meeting attendance rate (all Auditors)	%	100.0	96.4	96.4
Number of meetings of the Board of Corporate Auditors	Time	7	8	8
Number of meetings of the Nomination and Remuneration Committee	Time	1	1	1

Corruption prevention

	Unit	FY2022	FY2023	FY2024
Fines, penalties, and settlement costs related to bribery and anti-corruption violations	1,000 yen	0	0	0
Number of disciplinary dismissal cases due to bribery and anti-corruption violations	Case	0	0	0
Amount of direct political contributions	1,000 yen	0	0	0

Sustainability

ESG Data

Environment

Hisamitsu Pharmaceutical Group’s CO₂ emissions（Scope 1 & 2）

CO₂ emissions in the supply chain(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated]; Scope 1, 2, and 3)

Energy consumption (Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

Energy consumption by type (Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

Energy consumption at overseas factories

Water withdrawal by water source and drainage volume by destination (Hisamitsu Pharmaceutical Group)

Water withdrawal and drainage volumes at overseas factories

Water withdrawals in water-stressed areas

Water intake, drainage volume, and water pollutant emissions(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

Total waste emissions / Final waste disposal volume / Recycling rate(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

Waste emissions at overseas factories

Management of Specified Chemical Substances(Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

Air pollutant emissions (Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

Acquisition status of ISO 14001 certification

Acquisition status of ISO 45001 certification

Compliance with environmental laws and regulations (Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

Environmental accountingEnvironmental Conservation Cost (Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])Unit: 1,000 yen

Environmental Conservation Effect (Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])

Percentage of hybrid vehicles in all corporate sales vehicles (Hisamitsu Pharmaceutical Co., Inc. [Non-consolidated])